Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
8.00
-0.77 (-8.78%)
At close: May 21, 2025, 4:00 PM
8.10
+0.10 (1.25%)
Pre-market: May 22, 2025, 7:28 AM EDT
Evolent Health Stock Forecast
Stock Price Forecast
According to 14 professional analysts, the 12-month price target for Evolent Health stock ranges from a low of $12 to a high of $35. The average analyst price target of $16.79 forecasts a 109.87% increase in the stock price over the next year.
Price Target: $16.79 (+109.87%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Evolent Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 6 | 6 | 6 | 6 | 6 |
| Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 13 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +87.50% | May 13, 2025 |
| UBS | UBS | Strong Buy Maintains $14 → $15 | Strong Buy | Maintains | $14 → $15 | +87.50% | May 9, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $13 | Buy | Reiterates | $13 | +62.50% | Apr 28, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | +75.00% | Apr 10, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $13 → $12 | Buy | Maintains | $13 → $12 | +50.00% | Mar 10, 2025 |
Financial Forecast
Revenue This Year
2.08B
from 2.55B
Decreased by -18.78%
Revenue Next Year
2.40B
from 2.08B
Increased by 15.76%
EPS This Year
0.43
from -0.81
EPS Next Year
0.63
from 0.43
Increased by 48.16%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.2B | 2.7B | 3.2B | ||
| Avg | 2.1B | 2.4B | 2.7B | ||
| Low | 2.0B | 2.2B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -14.4% | 29.1% | 34.1% | ||
| Avg | -18.8% | 15.8% | 14.3% | ||
| Low | -23.1% | 5.3% | 4.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.79 | 0.87 | 1.16 | ||
| Avg | 0.43 | 0.63 | 0.87 | ||
| Low | 0.16 | 0.41 | 0.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 104.7% | 83.1% | ||
| Avg | - | 48.2% | 38.4% | ||
| Low | - | -3.3% | 13.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.